Imunon (IMNN) vs KALA BIO (KALA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Imunon is the larger company by market cap ($6.0 million vs $5.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMNN | KALA |
|---|---|---|
| Share price | $1.07 | $0.2966 |
| Market cap | $6.00M | $5.74M |
| 1-day change | -4.46% | -17.61% |
| EPS (TTM) | $-3.84 | $-10.71 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.39 | $95.50 |
| 52-week low | $1.03 | $0.2915 |
| Distance from 52-week high | -80.15% | -99.69% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +1488.79% | — |
| Average volume | 155.30K | 1.46M |
| Shares outstanding | 5.61M | 19.34M |
| Employees | 20 | 6 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Imunon
IMNN stock →Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy that is in a Phase 3 clinical trial for the localized treatment of advanced ovarian cancer, as well as in the IND-enabling phase for colorectal and pancreatic cancers, and in the discovery phase for glioblastoma.
Healthcare · Biotechnology · 20 employees
About KALA BIO
KALA stock →KALA BIO, Inc., a biopharmaceutical company, engages in the development of an on-premises artificial intelligence (AI) infrastructure platform for biotechnology research applications in the United States. The company develops Researgency, an agentic AI research platform for private enterprise AI deployment.
Healthcare · Biotechnology · 6 employees
IMNN vs KALA FAQ
Which is bigger, Imunon or KALA BIO?
Imunon (IMNN) is larger, with a market capitalization of $6.00M compared with $5.74M for KALA BIO (KALA).
Are Imunon and KALA BIO in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.